Fennec Pharmaceuticals Inc. (FENC): Total Assets
$70.55M
As of 2025-12-31
$75.75M
As of 2026-06-30
+37.8%
3-year compound annual growth
+17.6%
5-year compound annual growth
n/m
10-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $70.55M | +57.0% | 2026-03-27, Balance as of period end |
| 2024-12-31 | $44.95M | +67.3% | 2026-03-27, Balance as of period end |
| 2023-12-31 | $26.86M | n/a | 2025-03-26, Balance as of period end |
| 2023-09-30 | $19.98M | n/a | 2024-03-29, Balance as of period end |
| 2022-12-31 | $26.94M | +20.2% | 2024-03-29, Balance as of period end |
| 2021-12-31 | $22.41M | -28.7% | 2023-03-29, Balance as of period end |
| 2020-12-31 | $31.42M | +122.1% | 2022-02-28, Balance as of period end |
| 2019-12-31 | $14.15M | -38.4% | 2021-03-30, Balance as of period end |
| 2018-12-31 | $22.95M | -19.2% | 2020-02-14, Balance as of period end |
| 2017-12-31 | $28.40M | +615.0% | 2019-03-15, Balance as of period end |
| 2016-12-31 | $3.97M | +289.8% | 2018-03-28, Balance as of period end |
| 2015-12-31 | $1.02M | -57.0% | 2017-03-29, Balance as of period end |
| 2014-12-31 | $2.37M | +35.4% | 2016-03-28, Balance as of period end |
| 2013-12-31 | $1.75M | -25.9% | 2015-03-31, Balance as of period end |
| 2012-12-31 | $2.37M | -55.8% | 2014-03-31, Balance as of period end |
| 2011-12-31 | $5.35M | -10.7% | 2013-04-01, Balance as of period end |
| 2010-12-31 | $5.99M | n/a | 2012-03-27, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Fennec Pharmaceuticals Inc. (FENC) | 2025-12-31 | $70.55M | +57.0% |
| Editas Medicine, Inc. (EDIT) | 2025-12-31 | $186.53M | -45.4% |
| Voyager Therapeutics, Inc. (VYGR) | 2025-12-31 | $252.28M | -35.8% |
| Sangamo Therapeutics, Inc (SGMOQ) | 2025-12-31 | $59.74M | -41.2% |
| Kymera Therapeutics, Inc. (KYMR) | 2025-12-31 | $1.74B | +78.2% |
| Protalix BioTherapeutics, Inc. (PLX) | 2025-12-31 | $82.35M | +12.2% |
| Invivyd, Inc. (IVVD) | 2025-12-31 | $276.88M | +113.8% |
| C4 Therapeutics, Inc. (CCCC) | 2025-12-31 | $359.07M | +2.7% |
| X4 Pharmaceuticals, Inc (XFOR) | 2025-12-31 | $290.46M | +98.3% |
Compare FENC, EDIT, VYGR, SGMOQ side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗